The clinical implications and management of concomitant hypertension and dyslipidemia

Postgraduate Medicine

Volumn 119, Issue 2, 2006, Pages

  Nash, David T ^a  

^a SUNY UPSTATE MEDICAL UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMLODIPINE; ANTIHYPERTENSIVE AGENT; ANTILIPEMIC AGENT; ATORVASTATIN; BILE ACID SEQUESTRANT; EZETIMIBE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; NICOTINIC AGENT; VALSARTAN;

ATHEROSCLEROSIS; BLOOD PRESSURE; BODY MASS; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CLINICAL TRIAL; DIET THERAPY; DYSLIPIDEMIA; ESSENTIAL HYPERTENSION; EXERCISE; HIGH RISK POPULATION; HUMAN; HYPERTENSION; LIFESTYLE; MORBIDITY; MORTALITY; OBESITY; PREVALENCE; REVIEW; SEX DIFFERENCE; RISK FACTOR;

CARDIOVASCULAR DISEASES; DYSLIPIDEMIAS; HUMANS; HYPERTENSION; RISK FACTORS;

EID: 85047278654     PISSN: 00325481     EISSN: 12182583     Source Type: Journal    
DOI: 10.3810/pgm.2006.07.1744     Document Type: Review

References (24)

1. Chobanian AV, Bakris GL, Black HR, et al, and the National High Blood Pressure Education Program Coordinating Committee . The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. The JNC 7 report JAMA 2003; 289( 19): 2560-72[Erratum, JAMA 2003;290(2):197]
2. Expert Panel on Detection Evaluation and Treatment of High Blood Cholesterol in Adults . Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) JAMA 2001; 285( 19): 2486-97
3. Grundy SM, Cleeman JI, Bairey Merz CN, et al. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III Guidelines Circulation 2004; 110( 2): 227-39[Erratum, Circulation 2004;110(6):763]
4. Wilson PW, Kannel WB, Silbershatz H, et al. Clustering of metabolic factors and coronary heart disease Arch Intern Med 1999; 159( 10): 1104-9
5. Pearson TA, Mensah GA, Alexander RW, et al. Markers of inflammation and cardiovascular disease: application to clinical and public health practice; a statement for healthcare professionals from the Centers for Disease Control and Prevention and the American Heart Association Circulation 2003; 107( 3): 499-511
6. Wolf-Maier K, Cooper RS, Banegas JR, et al. Hypertension prevalence and blood pressure levels in 6 European countries, Canada, and the United States JAMA 2003; 289( 18): 2363-9
7. Ford ES, Mokdad AH, Giles WH, et al. Serum total cholesterol concentrations and awareness, treatment, and control of hypercholesterolemia among US adults: findings from the National Health and Nutrition Examination Survey, 1999 to 2000 Circulation 2003; 107 ( 17): 2185-9
8. Kannel WB. Fifty years of Framingham Study contributions to understanding hypertension J Hum Hypertens 2000; 14( 2): 83-90
9. Thomas F, Bean K, GuizeL, et al. Combined effects of systolic blood pressure and serum cholesterol on cardiovascular mortality in young (<55 years) men and women Eur Heart J 2002; 23( 7): 528-35
10. O'Meara JG, Kardia SLR, Armon JJ, et al. Ethnic and sex differences in the prevalence, treatment, and control of dyslipidemia among hypertensive adults in the GENOA study Arch Intern Med 2004; 164( 12): 1313-8
11. Brown CD, Higgins M, Donato KA, et al. Body mass index and the prevalance of hypertension and dyslipidemia Obes Res 2000; 8( 9): 605-19
12. Mason RP . Atheroprotective effects of long-acting dihydropyridine-type calcium channel blockers: evidence from clinical trials and basic scientific research Cerebrovasc Dis 2003; 16( Suppl 3): 11-7
13. Wong ND, Pio JR, Franklin SS, et al. Preventing coronary events by optimal control of blood pressure and lipids in patients with the metabolic syndrome Am J Cardiol 2003;91( 12): 1421-6
14. Neal B, MacMahon S, Chapman N; Blood Pressure Lowering Treatment Trialists' Collaboration . Effects of ACE inhibitors, calcium antagonists, and other blood-pressure-lowering drugs: results of prospectively designed overviews of randomised trials Lancet 2000; 355( 9246):1955-64
15. Weber MA, Julius S, Kjeldsen SE, et al. Blood pressure dependent and independent effects of antihypertensive treatment on clinical events in the VALUE trial Lancet 2004; 363( 9426): 2049-51
16. ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group . Major outcomes in moderately hypercholesterolemic, hypertensive patients randomized to pravastatin vs usual care: the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT-LLT) JAMA 2002;288( 23): 2998-3007
17. Heart Protection Study Collaborative Group . MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial Lancet 2002; 360( 9326): 7-22
18. Julius S, Kjeldsen SE, WeberM, et al; VALUE trial group . Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomized trial Lancet 2004; 363( 9426): 2022-31
19. Sever PS, Dahlof B, Poulter NR, et al; ASCOT investigators . Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial-Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial Lancet 2003; 361( 9364): 1149-58
20. Hajjar I, Kotchen TA . Trends in prevalence, awareness, treatment, and control of hypertension in the United States, 1988-2000 JAMA 2003; 290( 2): 199-206
21. Dezii CM . A retrospective study of persistence with single-pill combination therapy vs concurrent two-pill therapy in patients with hypertension Manag Care 2000; 9( 9 Suppl): 2-6
22. Wald NJ, Law MR . A strategy to reduce cardiovascular disease by more than 80% BMJ 2003; 326( 7404): 1419 [Erratum, BMJ 2003;327(7415):586]
23. Battleman DS, Peterson ED . Estimated prevalence of comorbid hypertension and dyslipidemia and therapeutic goal attainment among US adults in 2000, utilizing data from the National Health and Nutrition Examination Survey (NHANES III). (Abstr) J Manag Care Pharm 2004; 10( 2): 186
24. Chapman RH, Benner JS, Petrilla AA, et al. Adherence with concomitant antihypertensive and lipid-lowering therapy. (Abstr) Circulation 2003; 108( 17 Suppl IV): IV-756-7